首页> 美国卫生研究院文献>other >Resistance of Sézary Cells to TNF-α-Induced Apoptosis Is Mediated in Part by a Loss of TNFR1 and a High Level of the IER3 Expression
【2h】

Resistance of Sézary Cells to TNF-α-Induced Apoptosis Is Mediated in Part by a Loss of TNFR1 and a High Level of the IER3 Expression

机译:Sézary细胞对TNF-α-诱导的细胞凋亡的抗性部分通过TNFR1的丧失和高水平的IER3表达介导

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Failure to execute an apoptotic program is one of the critical steps and a common mechanism promoting tumorogenesis. Immediate early responsive gene 3 (IER3) has been shown to be upregulated in several cancers. IER3 is a stress induced gene, which upregulation leads to reduction in production of reactive oxygen species (ROS) protecting malignant cells from apoptosis. We observed that malignant lymphocytes from patients with Sézary syndrome (SzS) were resistant to pro-apoptotic dose of tumor necrosis factor-α (TNF-α). The aim of this study was to investigate the role of IER3 in the mechanism of such resistance. CD4+ CD26− lymphocytes from the peripheral blood of patients with SzS and healthy controls were negatively selected using CD4 and CD26 magnetic beads and analyzed for expression of TNFR1, TNFR2, IER3 expression, and ROS production in response to TNF-α at an apoptotic dose. Sézary cells with a higher level of IER3 expression retained their viability to TNF-α. IER3 upregulation correlated with a decrease level of intracellular ROS and low TNFR1 expression on malignant cells. Targeting IER3 could be of interest for the development of future therapeutic strategies for patients with SzS.
机译:未能执行凋亡程序是促进肿瘤发生的关键步骤之一和常见机制。已在几种癌症中显示出立即早期敏感基因3(IER3)将上调。 IER3是一种应激诱导的基因,其上调导致在凋亡中保护恶性细胞的反应性氧物质(ROS)的产生。我们观察到来自Sézary综合征(SZS)患者的恶性淋巴细胞耐受促凋亡剂量的肿瘤坏死因子-α(TNF-α)。本研究的目的是探讨IER3在这种抵抗力机制中的作用。使用CD4和CD26磁珠的SZs和健康对照患者外周血的CD4 + CD26-淋巴细胞,并在凋亡剂量下对TNFR1,TNFR2,IER3表达和ROS产生的表达进行了分析。 Sézary细胞具有较高水平的IER3表达,将其存活率保持在TNF-α。 IER3上调与恶性细胞细胞内ROS和低TNFR1表达的降低相关。目标IER3可能对SZS患者的未来治疗策略的发展感兴趣。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号